Joseph Domachowske, MD

A的安全性、免疫原性和有效性的2/2B期随机试验 健康成人和青少年的寨卡病毒DNA疫苗
Read more

一项IIIA期，随机，单盲，多中心研究，以评估免疫原性， 三剂Pediarix®的反应原性和安全性, Hiberix®和prevar 13®联合使用时 两剂无pcv液体制剂的GSK生物制剂的口服减毒HRV活疫苗 与目前许可的6-12岁健康婴儿HRV疫苗冻干制剂相比 weeks of age.
Read more

A study to evaluate safety, 基于黑猩猩衍生腺载体(ChAd155-RSV)(GSK3389245A)编码的病毒蛋白的GSK Biologicals RSV疫苗在RSV血清阳性婴儿中的反应原性和免疫原性.
Read more

A Phase 2b Randomized, Double-blind, 评价MEDI8897安全性和有效性的安慰剂对照研究, 抗呼吸道合胞病毒延长半衰期的单克隆抗体, in Healthy Preterm Infants
Read more

A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine with Aluminium in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in their Infants
Read more

A Phase 3, Randomized, Double-Blind, 评价一种人单克隆抗体的有效性和安全性的安慰剂对照研究, REGN2222, 预防经医疗护理的早产儿呼吸道合胞病毒感染
Read more

孕妇及其新生儿免疫状况及呼吸道合胞病毒和巨细胞病毒感染率的流行病学研究
Read more

A prospective, 流行病学研究评估呼吸道合胞病毒(RSV)与疾病负担的相关性, 新生儿疑似下呼吸道感染(LRTIs), from birth up to 2 years of age.
Read more

A single-center in vitro study to evaluate GSK 1325756 inhibition of CD11b cell surface expression in healthy adults and respiratory syncytial virus-infected children <2 years
Read more

GSK Biologicals的四价流感疫苗(GSK2282512A)与Fluzone®四价疫苗在6 - 35月龄儿童中的免疫原性和安全性研究. 201234 (FLU-Q-QIV-022)
Read more